Dupilumab improves pediatric type 2 asthma outcomes independent of patient baseline characteristics.

导出 LinkOut

翻译打印收藏纠错

作者： Jorge F,Maspero ^[1] ; Alessandro G,Fiocchi ^[2] ; Antoine,Deschildre ^[3] ; Leonard B,Bacharier ^[4] ; Arman,Altincatal ^[5] ; Elizabeth,Laws ^[6] ; David J,Lederer ^[7] ; Bolanle,Akinlade ^[7] ; Megan,Hardin ^[5]

作者单位： Fundación CIDEA, Buenos Aires, Argentina. Electronic address: jorge.maspero@fundacioncidea.org.ar. ^[1] Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. ^[2] Pediatric Pulmonology and Allergy Department, CHU Lille, Hôpital Jeanne de Flandre, Université de Lille, Lille, France. ^[3] Division of Allergy, Immunology and Pulmonary Medicine, Monroe Carell Jr. Children's Hospital at Vanderbilt University Medical Center, Nashville, Tenn. ^[4] Sanofi, Cambridge, Mass. ^[5] Sanofi, Bridgewater, NJ. ^[6] Regeneron Pharmaceuticals Inc., Tarrytown, New York, NY. ^[7]

DOI 10.1016/j.jaip.2024.08.010

PMID 39127101

发布时间 2024-11-08

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

The journal of allergy and clinical immunology. In practice

2024年12卷11期

3135-3138.e2页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Dupilumab improves pediatric type 2 asthma outcomes independent of patient baseline characteristics.

The journal of allergy and clinical immunology. In practice

相似文献

The journal of allergy and clinical immunology. In practice

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Dupilumab improves pediatric type 2 asthma outcomes independent of patient baseline characteristics.

The journal of allergy and clinical immunology. In practice

相似文献

The journal of allergy and clinical immunology. In practice

相关期刊

检索历史清除